Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy

NCT00566852 is registered in ClinicalTrials.gov with Radiation Therapy Oncology Group as lead sponsor.

NCT NCT00566852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00566852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy
Lead sponsor
Radiation Therapy Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2008
Completion date
December 31, 2016
Enrollment
554 (actual)
Sites
235

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive/functional effects, metastatic cancer, neurotoxicity, unspecified adult solid tumor, protocol specific